When will the VARIBAR THIN LIQUID patents expire, and when will VARIBAR THIN LIQUID go generic?

Sponsor	Phase
Northwell Health	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	VARIBAR THIN LIQUID	barium sulfate	FOR SUSPENSION;ORAL	208036-004	Apr 30, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 22, 2026

Varibar Thin Liquid (budesonide) market dynamics and financial trajectory: sales trends, payer/coverage drivers, and exclusivity-to-generic risk

Varibar Thin Liquid (budesonide; oral inhalation suspension via nebulizer) is a niche branded corticosteroid in the U.S. for the prophylaxis of bronchospasm in pediatric patients with persistent asthma who can use nebulized therapy. Market performance is shaped by (1) pediatric asthma treatment mix, (2) payer step therapy and formulary positioning versus alternative inhaled corticosteroid (ICS) products, and (3) channel sensitivity to pharmacy reimbursement mechanics and nebulizer-administered “convenience” products. Commercial trajectory is also constrained by patent and exclusivity timelines that determine when lower-cost “thin liquid” and related generic ICS options can pressure price.

Core commercial thesis: Varibar Thin Liquid has structurally lower addressable volume than large-category ICS leaders, so financial outcomes track pediatric asthma prevalence and guideline-driven prescribing more than adult market expansion. Long-run revenue is primarily a function of (a) whether the product maintains preferred status versus competing nebulized budesonide competitors and other ICS classes, and (b) time to meaningful generic erosion under FDA regulatory pathways.

What drives Varibar Thin Liquid (budesonide) market demand in pediatric asthma?

Demand drivers that typically decide net sales path for pediatric nebulized budesonide:

Pediatric asthma severity mix: prescriptions concentrate in patients needing ICS maintenance but with adherence barriers that nebulization can mitigate.
Care setting substitution: hospital outpatient and clinic prescribing patterns can shift quickly when formularies or payer prior authorization rules change.
Guideline adherence and controller therapy uptake: market growth correlates with the rate at which clinicians move children to consistent controller ICS use.
Delivery-system friction: nebulization often faces caregiver time constraints and home-nebulizer availability, which limits share versus metered-dose inhalers and DPI devices where coverage allows.

Competitive substitution pressure:

Other ICS formulations (both nebulized and device-based) compete on insurance coverage tiers, copay structure, and ease of use.
Class-based negotiation: pharmacy benefit managers tend to steer to preferred ICS products when multiple equivalents are available and when clinical outcomes are treated as comparable.

How do payer coverage and pharmacy reimbursement affect Varibar Thin Liquid net revenue?

Formulary and utilization mechanics that determine realized net pricing:

Preferred vs non-preferred status: net sales tend to compress when Varibar Thin Liquid is moved to non-preferred tiers.
Prior authorization triggers: step therapy and documentation requirements limit eligible prescriptions and shift volume to alternatives.
Copay support availability: when brand manufacturer support reduces patient out-of-pocket cost, scripts can rise even if list price is stable; when support narrows, demand softens.
Contracting dynamics with PBMs: aggressive rebate strategies can keep a niche product viable, but they raise the revenue dependency on contract renewals and utilization volume.

Channel sensitivity:

Pediatric nebulized products are exposed to pharmacy channel stocking and seasonal demand.
Net pricing is typically more volatile around contract resets than around seasonal respiratory patterns.

What is the revenue trajectory pattern for niche branded nebulized corticosteroids like Varibar Thin Liquid?

Typical branded trajectory for smaller-volume respiratory niche products:

Early ramp: initial adoption phase depends on guideline uptake, formulary build, and clinician comfort with the delivery method.
Midlife stabilization: net sales flatten when market share saturates and payer contracting matures.
Late-life decline: begins when generic/biosimilar-adjacent competition becomes practical, when exclusivity lapses, or when payer policies reduce branded access.

What to watch for in financial reporting:

Prescription count vs net price: niche products usually show more sensitivity to prescription volume than to price increases.
Contractual rebate movement: shifts in PBM rebate structures can move net sales without changes to gross demand.
Seasonality: winter respiratory peaks can create quarterly volatility; long-run trajectory is assessed on trailing twelve-month trends.

What patents protect Varibar Thin Liquid (budesonide) in the U.S., and how strong is the estate?

Patent-logic for commercial risk (how the estate usually maps to product erosion):

Composition-of-matter for budesonide is long expired.
Protection typically shifts to specific formulation attributes, delivery system characteristics, manufacturing methods, or use claims that sustain brand exclusivity against full generic substitution.
For nebulized “thin liquid” presentations, the relevant risk is whether generic manufacturers can design around by changing formulation parameters, particle/viscosity controls, or container/administration characteristics.

Commercial consequence:

If remaining enforceable patents are formulation- or process-tethered, generics can enter in some forms while risking injunctions or carve-outs for certain attributes.
If method-of-use or dosing regimen claims remain, launch timing can be delayed until “non-infringing” labeling or distribution design is agreed or adjudicated.

(Note: a precise, named patent list with expiration dates and asserted/defended claims requires Orange Book and litigation docket linkage, which is not provided in the prompt.)

When does Varibar Thin Liquid lose exclusivity, and when would generic entry become likely?

Exclusivity-to-entry framework for branded drugs:

Regulatory exclusivity (Orange Book “patent” and regulatory exclusivity periods) defines the earliest legal time for certain generic approvals.
Patent litigation outcomes determine whether the first generic is authorized immediately on the legal “earliest date,” or delayed by automatic stays/agreements.
Paragraph IV settlement terms often compress time-to-erosion, especially for niche products where one launch quickly shifts payer behavior.

Generic entry likelihood for niche budesonide products:

The first meaningful volume shock usually coincides with the first fully substitutable generic and payer re-contracting.
Even after approval, net sales erosion can be delayed by formulary update cycles and prior authorization changes.

(Specific dates cannot be stated without Orange Book/approval history.)

Which companies are likely competitors to Varibar Thin Liquid, and how do substitution patterns typically shift?

Competition map typically used by payers:

Nebulized budesonide equivalents: direct substitution where formulation and labeling match payer criteria.
Alternative nebulized ICS products: substitution based on insurance tier and copay.
Device-based ICS: substitution when payer coverage prefers lower cost options and patients can transition caregivers and devices.

How substitution usually occurs commercially:

Brand share declines first at the margin: patients with active prescriptions keep therapy until refills, prior authorizations expire, or the PBM contract changes.
Then volume shifts at scale once the preferred generic is added to the formulary and prior auth rules become permissive for the cheaper option.

What formulation and delivery-system changes create generic entry barriers for thin liquid budesonide?

Barrier dimensions for nebulized formulations:

Viscosity and “thin liquid” specification affects atomization and deposition in airways.
Suspension stability and particle dispersion can affect therapeutic consistency and manufacturability.
Container and administration characteristics can matter for product performance and labeling.
Manufacturing process controls can be protected via process patents or can drive bioavailability and performance equivalence evidence burdens.

Commercial impact:

If generic manufacturers face stability or performance proving friction, launch can slip even after legal eligibility.
If the market supports multiple equivalent products, payer may shift demand to the fastest-to-launch alternative, not necessarily the lowest-cost one.

What FDA status and Orange Book posture applies to Varibar Thin Liquid?

Orange Book “posture” is the practical determinant of generic risk:

Drugs with multiple listed patents across formulation, method, and device attributes often face delayed generic entry or carve-outs by design.
The FDA listing also signals whether the product has been subject to multiple reformulations, which can create layered protection for specific NDAs or strengths.

(Orange Book listings are not provided in the prompt, so a specific status cannot be stated.)

How does Varibar Thin Liquid compare with other budesonide nebulized products and ICS alternatives on market positioning?

Comparison factors used by payers and providers:

Device and caregiver burden: nebulized liquid vs inhaler-based ICS.
Dosing convenience: total daily dose schedule and administration time.
Formulary tier and PA requirements.
Clinical perception: perceived equivalence within pediatric asthma subpopulations.

Market positioning pattern for niche nebulized ICS:

Brand differentiation is typically not efficacy class leadership. It is practical use in patient settings and payer contracting.
When competing ICS products are included on the preferred tier, niche products can lose share even if clinical outcomes are treated as comparable.

What patent litigation or Paragraph IV challenges affect Varibar Thin Liquid launch timelines?

How litigation shapes commercial trajectory:

Patent infringement suits can trigger automatic stays that delay generic approval and reduce near-term erosion risk.
Settlements can enable “at-risk” launch timing or delayed launches with label carve-outs.

(No litigation docket or Paragraph IV history is included in the prompt.)

What would a “generic launch scenario” imply for Varibar Thin Liquid pricing and revenue?

Typical niche branded revenue erosion profile after first generic launch:

Gross margin compression: even with list price maintained, net price drops due to competitive pressure and PBM contracting.
Volume shock: scripts shift quickly once formulary status changes from brand-preferred to generic-preferred.
Second-generic acceleration: additional entries compound erosion as PBMs negotiate deeper rebates.

What matters most for financial outcomes:

Whether the first generic is fully substitutable by label.
How quickly PBMs update formulary tiers and prior authorization policies.
Whether the brand offers a bridge strategy via rebates/coupons and whether competing products are similarly covered.

Key Takeaways

Varibar Thin Liquid’s financial trajectory is primarily driven by pediatric asthma controller substitution behavior, formulary/PA mechanics, and contracted net pricing, not broad adult ICS category growth.
Niche volume makes revenue more sensitive to coverage tier changes and first generic substitution timing.
The long-run path depends on the remaining formulation/delivery/processing patent landscape and whether it delays full substitution through injunctions, stays, or design-around labeling.
A realistic erosion path after exclusivity ends is driven by fast PBM formulary re-tiering, which often creates a sharper volume decline than price adjustments alone.

FAQs

1) Is Varibar Thin Liquid treated as interchangeable with other nebulized budesonide products by payers?

Typically, interchangeability depends on formulary criteria, labeling match, and patient eligibility rules embedded in prior authorization. Payer contracts often define preferred substitutes by NDA product and strength.

2) How do seasonal respiratory patterns influence Varibar Thin Liquid sales?

Net sales commonly show quarterly seasonality tied to winter respiratory demand, while long-run trajectory is determined by year-over-year prescription trends and formulary access.

3) What factors determine whether a generic can launch as “thin liquid” budesonide and avoid infringement?

Generic viability usually hinges on whether formulation attributes (thin liquid viscosity and stability), manufacturing controls, and labeling can be implemented without infringing formulation/process patents.

4) Do Paragraph IV settlements usually accelerate generic erosion for niche respiratory brands?

Settlements frequently do. Even when entry is delayed, PBM contracting often re-routes volume once launch is credibly imminent.

5) Which commercial lever matters most for brand survival after exclusivity wanes?

Contract renegotiation and the speed of formulary repricing after generic entry, especially ensuring continued preferred status or maintaining patient access through rebate-backed patient pricing.

References (APA)

No sources were provided in the prompt, and no Orange Book, FDA, or litigation documents were included; therefore no citations can be listed without inventing references.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	1
Patent Applications:	3,095
What excipients (inactive ingredients) are in VARIBAR THIN LIQUID?	VARIBAR THIN LIQUID excipients list
DailyMed Link:	VARIBAR THIN LIQUID at DailyMed

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

VARIBAR THIN LIQUID Drug Patent Profile

Which patents cover Varibar Thin Liquid, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for VARIBAR THIN LIQUID

Recent Clinical Trials for VARIBAR THIN LIQUID

Pharmacology for VARIBAR THIN LIQUID

US Patents and Regulatory Information for VARIBAR THIN LIQUID